Skip to main content

Advertisement

Log in

Significance of Plasma Cytokine Levels in Melanoma Patients With Histologically Negative Sentinel Lymph Nodes

  • Original Articles
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Introduction:Although sentinel lymph node (SLN) status is the most powerful predictor of prognosis in patients with clinically localized melanoma, a proportion of melanoma patients with histologically negative SLNs will still recur. It is hypothesized that tumor response may be altered or mediated by specific cytokines. We therefore investigated whether levels of IL-4, IL-6, IL-10, TNF-α, or IFN-γ would predict disease recurrence in melanoma patients with histologically negative SLNs.

Methods:This prospective cohort study involved 218 patients with clinically localized melanoma who underwent a histologically negative SLN biopsy. Preoperative plasma cytokine levels were determined by enzyme-linked immunosorbent assay on these patients, as well as on 90 healthy controls. Kaplan-Meier life tables were constructed, and Cox proportional hazards analyses were performed to assess predictors of disease-free survival (DFS).

Results:At a median follow-up of 43 months, 33 of 218 patients (15%) had suffered disease recurrence. Melanoma patients had significant elevations of IL-4, IL-6, and IL-10 compared to healthy controls; levels of IFN-γ were less elevated in melanoma patients compared to controls. Despite this, melanoma patients with detectable IFN-γ levels were at significantly higher risk for recurrence compared to patients with undetectable levels (5-year DFS 70% vs. 86%, P = .03). On multivariate analysis including standard melanoma prognostic factors, only tumor thickness (P = .004) and the presence of detectable IFN-γ levels (P = .05) were significant independent prognostic factors for disease-free survival.

Conclusions:Among melanoma patients with clinically localized disease who have undergone a histologically negative SLN biopsy, presence of a detectable plasma level of IFN-γ is an independent predictor of disease recurrence. Elevated levels of IFN-γ may identify a group of early-stage melanoma patients who are more likely to have recurrence of disease and who may benefit from adjuvant therapies, including immunotherapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Morton D, Wen D, Wong J, et al. Technical details of intraoperative lymphatic mapping in early stage melanoma. Arch Surg 1992; 127: 392–9.

    CAS  PubMed  Google Scholar 

  2. Ross M, Reintgen DS, Balch C. Selective lymphadenectomy: emerging role of lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Semin Surg Oncol 1993; 9: 219–23.

    CAS  PubMed  Google Scholar 

  3. Gershenwald JE, Tseng C, Thompson W, et al. Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery 1998; 124: 203–10.

    PubMed  CAS  Google Scholar 

  4. Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998; 16: 2253–60.

    CAS  PubMed  Google Scholar 

  5. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17: 1–8.

    Google Scholar 

  6. Wittke F, Hoffman R, Buer J. Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma. Br J Cancer 1999; 79: 1182–4.

    PubMed  CAS  Google Scholar 

  7. Tartour E, Dorval T, Mosseri V, et al. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 1994; 69: 911–3.

    PubMed  CAS  Google Scholar 

  8. Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Brocker EB. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 1995; 5: 67–8.

    PubMed  CAS  Google Scholar 

  9. Colombo MP, Maccalli C, Mattei S, Melani C, Radrizzani M, Parmiani G. Expression of cytokine genes, including IL-6, in human malignant melanoma cell lines. Melanoma Res 1992; 2: 181–9.

    PubMed  CAS  Google Scholar 

  10. Luscher U, Filgueira L, Juretic A, Zuber M, Luscher NJ, Heberer M, Spagnoli GC. The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes. Int J Cancer 1994; 57: 612–9.

    PubMed  CAS  Google Scholar 

  11. Chen Q, Daniel V, Maher DW, Hersey P. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma cells. Int J Cancer 1994; 56: 755–60.

    PubMed  CAS  Google Scholar 

  12. Lattime EC, Mastrangelo MJ, Bagasra O, LiW, Berd D. Expression of cytokine mRNA in human melanoma tissues. Cancer Immunol Immunother 1995; 41: 151–6.

    PubMed  CAS  Google Scholar 

  13. Singh RK, Gutman M, Radinsky R. Heterogeneity of cytokine and growth factor gene expression in human melanoma cells with different metastatic potentials. J Interferon Cytokine Res 1995; 15: 81–7.

    Article  PubMed  CAS  Google Scholar 

  14. Ciotti P, Rainero ML, Nicolo G, et al. Cytokine expression in human primary and metastatic melanoma cells: analysis in fresh bioptic specimens. Melanoma Res 1995; 5: 41–7.

    PubMed  CAS  Google Scholar 

  15. Dummer W, Bastian BC, Ernst N, Schanzle C, Schwaaf A, Brocker EB. Interleukin-10 production in malignant melanoma: preferential detection of IL-10 secreting tumor cells in metastatic lesions. Int J Cancer 1996; 66: 607–10.

    PubMed  CAS  Google Scholar 

  16. Brady MS, Eckels DD, Lee F, Ree SY, Lee JS. Cytokine production by CD4+ T-cells responding to antigen presentation by melanoma cells. Melanoma Res 1999; 9: 173–80.

    PubMed  CAS  Google Scholar 

  17. Kawakami Y, Rosenberg SA, Lotze MT. Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J Experimental Med 1988; 168: 2184–91.

    Google Scholar 

  18. Kirkwood JM, Bryant J, Schiller JH, Oken MM, Borden EC, Whiteside TL. Immunomodulatory function of interferon-gamma in patients with metastatic melanoma: results of a phase II-B trial in subjects with metastatic melanoma, ECOG study E 4987. J Immunotherapy 1997; 20: 146–57.

    Article  CAS  Google Scholar 

  19. Anichini A, Mortarini R, Fossati G, Parmiani G. Phenotypic profiles of clones from early cultures of human metastatic melanomas and its modulation by recombinant interferon γ. Int J Cancer 1986; 38: 505–11.

    PubMed  CAS  Google Scholar 

  20. Anichini A, Castelli C, Sozzi G, Fossati G, Parmiani G. Differential susceptibility to recombinant interferon-γ-induced HLA-DQ antigen modulation among clones from a human metastatic melanoma. J Immunol 1988; 140: 183–91.

    PubMed  CAS  Google Scholar 

  21. Maio M, Gulwani B, Morgano A, Ferrone S. Differential modulation by tumor necrosis factor and immune interferon of HLA class-II antigens expressed by melanoma cells. Int J Cancer 1989; 44: 554–9.

    PubMed  CAS  Google Scholar 

  22. Graham GM, Guarini L, Moulton TA, et al. Potentiation of growth suppression and modulation of the antigenic phenotype in human melanoma cells by the combination of recombinant human fibroblast and immune interferons. Cancer Immunol Immunother 1991; 32: 382–90.

    PubMed  CAS  Google Scholar 

  23. Worm M, Schadendorf D, Czarnetzki BM. Responsiveness to interferon treatment of human melanoma cells correlates to immunophenotype. Melanoma Res 1993; 3: 29–33.

    Article  PubMed  CAS  Google Scholar 

  24. Whitehead RP, Unger JM, Goodwin JW, Walker MJ, Thompson JA, Flaherty LE, Sondak VK. Phase II trial of recombinant human interleukin-4 in patients with disseminated malignant melanoma: a Southwest Oncology Group study. J Immunother 1998; 21: 440–6.

    PubMed  CAS  Google Scholar 

  25. Meyskens FL, Kopecky KJ, Taylor CW, et al. Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Natl Cancer Inst 1995; 87: 1710–13.

    PubMed  Google Scholar 

  26. BrockerE-B, Suter L, Sorg C. HLA-DR antigen expression in primary melanomas of the skin. J Invest Dermatol 1984; 82: 244–7.

    PubMed  CAS  Google Scholar 

  27. Brocker EB, Zwadlo G, Holzmann B, Macher E, Sorg C. Inflammatory cell infiltrates in human melanoma at different stages of tumor progression. Int J Cancer 1988; 41: 562–7.

    PubMed  CAS  Google Scholar 

  28. Taramelli D, Fossati G, Balsari A, Marolda R, Parmiani G. The inhibition of lymphocyte stimulation by autologous human metastatic melanoma cells correlates with the expression of HLA-DR antigens on the tumor cells. Int J Cancer 1984; 34: 797–806.

    PubMed  CAS  Google Scholar 

  29. Ruiter DJ, Mattijssen V, Broeker,E-B, Ferrone S. MHC antigens in human melanomas. Semin Cancer Biol 1991; 2: 5–45.

    Google Scholar 

  30. Becker JC, Brabletz T, Czerny C, Termeer C, Brocker EB. Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+ human T cell clone by the autologous MHC class II+ melanoma. Int Immunol 1993; 5: 1501–8.

    PubMed  CAS  Google Scholar 

  31. Perrey C, Pravica V, Sinnott PJ, Hutchinson IV. Genotyping for polymorphisms in interferon-γ, interleukin-10, transforming growth factor-β1 and tumor necrosis factor-α genes: a technical report. Transplant Immunol 1998; 6: 193–7.

    CAS  Google Scholar 

  32. Morse HR, Olomolaiye OO, Wood NA, Keen LJ, Bidwell JL. Induced heteroduplex genotyping of TNF-alpha, IL-1 beta, Il-6 and IL-10 polymorphisms associated with transcriptional regulation. Cytokine 1999; 11: 789–95.

    PubMed  CAS  Google Scholar 

  33. Awata T, Matsumoto C, Urakami T, Hagura R, Amemiya S, Kanazawa Y. Association of polymorphism in the interferon gamma gene with IDDM. Diabetologia 1994; 37: 1159–62.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jeffrey E. Gershenwald MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Porter, G.A., Abdalla, J., Lu, M. et al. Significance of Plasma Cytokine Levels in Melanoma Patients With Histologically Negative Sentinel Lymph Nodes. Ann Surg Oncol 8, 116–122 (2001). https://doi.org/10.1007/s10434-001-0116-3

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10434-001-0116-3

Key Words

Navigation